Protara Therapeutics Plans 2H 2027 BLA Submission for TARA-002 in LMs; $177M Cash Funds Operations into 2028
summarizeSummary
Protara Therapeutics announced its first-quarter 2026 financial results and provided a comprehensive business update. The company reported a strong cash position of approximately $177 million as of March 31, 2026, which is expected to fund planned operations into 2028, providing significant financial runway. A key development is the intention to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in the second half of 2027, following productive discussions with the FDA and a positive review division change. Additionally, Protara expects to complete enrollment for the ADVANCED-2 trial's BCG-Unresponsive cohort and initiate the ADVANCED-3 trial in BCG-Naïve patients in 2H 2026, alongside presenting updated data for TARA-002 in NMIBC and interim results for IV Choline Chloride in 2H 2026. These updates provide a clear regulatory path and multiple clinical milestones, which are highly material for a clinical-stage biotechnology company.
At the time of this announcement, TARA was trading at $5.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.6M. The 52-week trading range was $2.77 to $7.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.